Literature DB >> 28428051

Cell-penetrating peptide CGKRK mediates efficient and widespread targeting of bladder mucosa following focal injury.

James I Griffin1, Siu Kit Kevin Cheng2, Tomoko Hayashi2, Dennis Carson2, Manju Saraswathy3, Devatha P Nair3, Dmitri Simberg4.   

Abstract

The bladder presents an attractive target for topical drug delivery. The barrier function of the bladder mucosa (urothelium) presents a penetration challenge for small molecules and nanoparticles. We found that focal mechanical injury of the urothelium greatly enhances the binding and penetration of intravesically-administered cell-penetrating peptide CGKRK (Cys-Gly-Lys-Arg-Lys). Notably, the CGKRK bound to the entire urothelium, and the peptide was able to penetrate into the muscular layer. This phenomenon was not dependent on intravesical bleeding and was not caused by an inflammatory response. CGKRK also efficiently penetrated the urothelium after disruption of the mucosa with ethanol, suggesting that loss of barrier function is a prerequisite for widespread binding and penetration. We further demonstrate that the ability of CGKRK to efficiently bind and penetrate the urothelium can be applied toward mucosal targeting of CGKRK-conjugated nanogels to enable efficient and widespread delivery of a model payload (rhodamine) to the bladder mucosa.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bladder; Delivery; Nanogel; Peptide; Urothelium

Mesh:

Substances:

Year:  2017        PMID: 28428051      PMCID: PMC5618708          DOI: 10.1016/j.nano.2017.04.004

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  25 in total

Review 1.  Local drug delivery to bladder using technology innovations.

Authors:  Pradeep Tyagi; Shachi Tyagi; Jonathan Kaufman; Leaf Huang; Fernando de Miguel
Journal:  Urol Clin North Am       Date:  2006-11       Impact factor: 2.241

2.  Novel in vitro model for studying ureteric stent-induced cell injury.

Authors:  Chelsea N Elwood; Dirk Lange; Richard Nadeau; Shannon Seney; Kelly Summers; Ben H Chew; John D Denstedt; Peter A Cadieux
Journal:  BJU Int       Date:  2009-11-03       Impact factor: 5.588

Review 3.  Cell-penetrating peptides: design, synthesis, and applications.

Authors:  Dana Maria Copolovici; Kent Langel; Elo Eriste; Ülo Langel
Journal:  ACS Nano       Date:  2014-02-28       Impact factor: 15.881

4.  Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Authors:  Lilach Agemy; Venkata R Kotamraju; Dinorah Friedmann-Morvinski; Shweta Sharma; Kazuki N Sugahara; Erkki Ruoslahti
Journal:  Mol Ther       Date:  2013-08-20       Impact factor: 11.454

Review 5.  New frontiers in intravesical therapies and drug delivery.

Authors:  Antonella Giannantoni; Savino M Di Stasi; Michael B Chancellor; Elisabetta Costantini; Massimo Porena
Journal:  Eur Urol       Date:  2006-08-30       Impact factor: 20.096

6.  R11, a novel cell-permeable peptide, as an intravesical delivery vehicle.

Authors:  Jer-Tsong Hsieh; Jian Zhou; Crystal Gore; Philippe Zimmern
Journal:  BJU Int       Date:  2011-03-31       Impact factor: 5.588

7.  Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel.

Authors:  Danny Chen; Di Song; M Guillaume Wientjes; Jessie L-S Au
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

8.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.

Authors:  Jason A Hoffman; Enrico Giraudo; Mallika Singh; Lianglin Zhang; Masahiro Inoue; Kimmo Porkka; Douglas Hanahan; Erkki Ruoslahti
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

9.  Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate.

Authors:  Paul J Hauser; David A Buethe; John Califano; Troy M Sofinowski; Daniel J Culkin; Robert E Hurst
Journal:  J Urol       Date:  2009-09-17       Impact factor: 7.450

10.  MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.

Authors:  Fanghong Chen; Guangjian Zhang; Yanli Cao; Martin J Hessner; William A See
Journal:  J Urol       Date:  2009-10-23       Impact factor: 7.450

View more
  1 in total

1.  Enhanced Anti-Glioma Efficacy by Borneol Combined With CGKRK-Modified Paclitaxel Self-Assembled Redox-Sensitive Nanoparticles.

Authors:  Lingyan Lv; Xinrui Li; Wei Qian; Shennan Li; Yan Jiang; Yaokun Xiong; Jianpei Xu; Wei Lv; Xiaoyan Liu; Yun Chen; Yulin Tang; Hongliang Xin
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.